An official website of the United States government
Abstract Rapid testing is essential to fighting pandemics such as coronavirus disease 2019 (COVID-19), the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Exhaled human breath contains multiple volatile molecules providing powerful potential for non-invasive diagnosis of diverse medical conditions. We investigated breath detection of SARS-CoV-2 infection using cavity-enhanced direct frequency comb spectroscopy (CE-DFCS), a state-of-the-art laser spectroscopic technique capable of a real-time massive collection of broadband molecular absorption features at ro-vibrational quantum state resolution and at parts-per-trillion volume detection sensitivity. Using a total of 170 individual breath samples (83 positive and 87 negative with SARS-CoV-2 based on reverse transcription polymerase chain reaction tests), we report excellent discrimination capability for SARS-CoV-2 infection with an area under the receiver-operating-characteristics curve of 0.849(4). Our results support the development of CE-DFCS as an alternative, rapid, non-invasive test for COVID-19 and highlight its remarkable potential for optical diagnoses of diverse biological conditions and disease states.
more »
« less
Revolutionising disease detection: The emergence of non-invasive VOC breathomics
Revolutionising disease detection: The emergence of non-invasive VOC breathomicsBreathomics marks a revolutionary approach to disease detection by analyzing the chemical composition of exhaled breath. As the world recovers from the recent global health crises, the detection and management of pandemic diseases like COVID-19, RSV, and flu have come to the forefront. The COVID-19 pandemic alone has affected over 96 million people in the US, with a devastating count of more than a million fatalities. Similarly, respiratory syncytial virus (RSV) and influenza (flu) collectively burden the healthcare system with millions of cases annually, leading to hundreds of thousands of hospitalizations and tens of thousands of deaths. These staggering statistics underscore an urgent need for diagnostic methods that are not only swift and accurate but also non- invasive to facilitate rapid, widespread testing. Enter Breathomics—a revolutionary approach that analyzes the chemical composition of exhaled breath to detect diseases.
more »
« less
- Award ID(s):
- 2200299
- PAR ID:
- 10528317
- Publisher / Repository:
- Open Access Government
- Date Published:
- Journal Name:
- Open Access Government
- Volume:
- 41
- Issue:
- 1
- ISSN:
- 2516-3817
- Page Range / eLocation ID:
- 74 to 75
- Subject(s) / Keyword(s):
- non-invasive VOC detection
- Format(s):
- Medium: X
- Sponsoring Org:
- National Science Foundation
More Like this
-
-
This paper presents sensor nanotechnologies that can be used for the skin-based gas “smelling” of disease. Skin testing may provide rapid and reliable results, using specific “fingerprints” or unique patterns for a variety of diseases and conditions. These can include metabolic diseases, such as diabetes and cholesterol-induced heart disease; neurological diseases, such as Alzheimer’s and Parkinson’s; quality of life conditions, such as obesity and sleep apnea; pulmonary diseases, such as cystic fibrosis, asthma, and chronic obstructive pulmonary disease; gastrointestinal tract diseases, such as irritable bowel syndrome and colitis; cancers, such as breast, lung, pancreatic, and colon cancers; infectious diseases, such as the flu and COVID-19; as well as diseases commonly found in ICU patients, such as urinary tract infections, pneumonia, and infections of the blood stream. Focusing on the most common gaseous biomarkers in breath and skin, which is nitric oxide and carbon monoxide, and certain abundant volatile organic compounds (acetone, isoprene, ammonia, alcohols, sulfides), it is argued here that effective discrimination between the diseases mentioned above is possible, by capturing the relative sensor output signals from the detection of each of these biomarkers and identifying the distinct breath print for each disease.more » « less
-
COVID-19 may present with a variety of clinical syndromes, however, the upper airway and the lower respiratory tract are the principle sites of infection. Previous work on respiratory viral infections demonstrated that airway inflammation results in the release of volatile organic compounds as well as nitric oxide. The detection of these gases from patients’ exhaled breath offers a novel potential diagnostic target for COVID-19 that would offer realtime screening of patients for COVID-19 infection.youmore » « less
-
The chemical composition of exhaled human breath can be strongly correlated to medical conditions such as lung cancer or gastrointestinal diseases. To establish these correlations and, most importantly, to use them in diagnostics, chemical gas detection needs to be performed at trace concentrations, typically at parts-per-million (ppm) levels or below, for many compounds simultaneously. Traditional methods such as gas chromatography, a workhorse in scientific laboratories, is ill-suited for the fast, inexpensive point-of-care diagnostics that would be needed to build statistically-meaningful ensembles over large populations. With the increasing availability and decreasing cost of high power diode lasers and of uncooled CMOS cameras, spontaneous Raman spectroscopy (SRS), a vibrational molecular fingerprinting tool, is emerging as an economic alternative. Although gas SRS scattering cross sections are only on the order of 10$$^{-31}$$ cm$^2$/sr, considerable progress in the development of enhancement techniques has been made over the past decade. The purpose of this work is to review SRS enhancement approaches in the context of established human breath tests, and to provide a comparison with alternatives. Already, numerous trace gases such as H$$_2$$, CH$$_4$$, $$^{13}$$CO$$_2$$, and volatile organic compounds like acetone can be rapidly quantified in breath at concentrations below 1 ppm with SRS. With improvements in resolution and design of enhancement systems, SRS-based sensors could be scalably deployed in, e.g., pharmacies, and non-invasively screen for dozens of analytes at the parts-per-billion level.more » « less
-
null (Ed.)Rationale To understand novel diseases, patients may draw comparisons to other diseases. Objective We examined whether mentally associating specific diseases with COVID-19 was related to self-reported protective behaviors early in the pandemic. Methods In March 2020, a national sample of 6534 U.S. adults listed diseases that came to mind when thinking of COVID-19. They self-reported protective behaviors, demographics, and COVID-19 risk perceptions. Results Participants associated COVID-19 with common infectious diseases like seasonal influenza (59%), common cold (11%), and pneumonia (10%), or emergent infectious diseases like pandemic influenza (28%), SARS/MERS (27%), and Ebola (14%). Seasonal influenza was most commonly mentioned, in all demographic groups. Participants mentioning seasonal influenza or common cold reported fewer protective behaviors. Those mentioning pneumonia or emergent infectious diseases reported more protective behaviors. Mentioning pneumonia, SARS/MERS, and Ebola was associated with the most protective behaviors, after accounting for other generated diseases, demographics, and risk perceptions (e.g., for avoiding crowds, OR = 1.52, 95% CI = 1.26, 1.83; OR = 1.28, 95% CI = 1.13, 1.46; OR = 1.30, 95% CI = 1.11, 1.52, respectively). Conclusions Early in the pandemic, most participants mentally associated COVID-19 with seasonal flu, which may have undermined willingness to protect themselves. To motivate behavior change, COVID-19 risk communications may need to mention diseases that resonate with people while retaining accuracy.more » « less
- Free Publicly Accessible Full Text
-
Accepted Manuscript1.0
- Journal Article:
- https://doi.org/10.56367/OAG-041-10923
